Aditxt ADTX

OTC ADTX

$0.01 +0.00 (+0.00%)

At close: Sep 8, 2026 · 4:00 PM EDT

Key Stats

Market Cap161.39

P/E0.00

P/S0.01

Div. Yield0.00

Total Debt (Qtr)3.31 Mn

Add ratio to table…

About

Aditxt, Inc. is a biotechnology company focused on developing immune modulation technologies and diagnostic platforms to address autoimmune diseases cancer and infectious diseases. Headquartered in Mountain View California the company was incorporated in Delaware in September 2017 and pursues a mission of decentralizing health innovation through stakeholder engagement. Its core activities include research and development of proprietary therapeutic candidates advancement of…

Aditxt, Inc. generates revenue primarily through licensing of its proprietary technologies to partners and collaborators. The company has entered into license agreements with Loma Linda University for its apoptotic DNA immunotherapy platform and with Stanford University for immune response detection technologies. It also grants sublicenses such as the non exclusive license for SARS CoV 2 antibody testing to a CLIA CAP certified laboratory and seeks future revenue from commercialization of its product candidates after regulatory approval.

The company operates through the following segments:

Adimune focuses on immune modulation therapeutic programs using its apoptotic DNA immunotherapy platform to induce tolerance in autoimmune diseases and transplant rejection. The lead candidate ADI 100 targets glutamic acid decarboxylase for potential treatment of type 1 diabetes psoriasis and central nervous system disorders. Pre clinical studies have demonstrated durable tolerance induction without impairing infection fighting capacity and have supported manufacturing of clinical grade drug substance for upcoming trials. Adimune has engaged contract research organizations and is preparing for clinical studies in psoriasis and type 1 diabetes with plans to evaluate stiff person syndrome in collaboration with the Mayo Clinic.
Pearsanta develops mitochondrial DNA based biomarkers for early detection of cancer and other diseases through its Mitomic technology platform. The company acquired the Mitomic assets from MDNA Life Sciences and operates a high complexity CLIA CAP accredited laboratory in Richmond Virginia to support assay development. Current product candidates include a blood based test for prostate cancer and a test for endometriosis while ongoing work seeks to identify biomarkers for ovarian lung pancreatic liver breast stomach esophageal and colorectal cancers.
Adivir is dedicated to advancing antiviral and antimicrobial solutions to address unmet needs in infectious disease and population health. The subsidiary focuses on identifying developing and commercializing therapeutic candidates for life threatening viral infections and emerging pathogens. Its strategy includes leveraging both novel and repurposed approaches to improve treatment access in underserved regions.
Adifem pursues women's health initiatives aiming to create innovative therapies for conditions with significant unmet medical need. Although the proposed acquisition of Evofem Biosciences was not completed the subsidiary continues to explore opportunities in contraception hormonal regulation and related therapeutic areas. Its efforts align with Aditxt's broader goal of expanding into underserved therapeutic sectors.

Aditxt, Inc. occupies a niche in the biotechnology sector where it combines immune tolerance induction with mitochondrial DNA based diagnostics to differentiate from conventional immunosuppression and broad spectrum antibody assays. Competitors in the immune tolerance space include companies pursuing antigen specific regulatory T cell therapies and cytokine blockers while in the diagnostic arena firms offering liquid biopsy and polygenic risk scores represent alternatives. The company's competitive advantages stem from its mechanism that mimics natural apoptosis to achieve antigen specific tolerance without global immune suppression and from its proprietary platforms that enable high sensitivity multiplexed detection of immune responses and mitochondrial DNA alterations.

Aditxt, Inc. serves patients physicians and research institutions through its therapeutic and diagnostic programs. Specific collaborators mentioned in the filing include the Mayo Clinic for clinical trial execution Loma Linda University and Stanford University for technology licensing and a CLIA CAP certified laboratory in Richmond Virginia that performs SARS CoV 2 antibody testing under a non exclusive agreement.

Investment Thesis

▲ Bull case

Aditxt's acquisition of Ignite Proteomics provides a significant strategic advantage in the precision oncology market, where Ignite's RPPA platform addresses a critical unmet need by measuring functional protein activity rather than just genomic expression, enabling more accurate therapy selection for targeted treatments like antibody drug conjugates. This technological differentiation is validated by peer-reviewed publication in npj Precision Oncology, demonstrating predictive value where conventional HER2 IHC failed, particularly in identifying TOPO1 expression in HER2-negative patients who may still benefit from T-DXd therapy. With Ignite already operating a CLIA-certified laboratory and having an established Medicare PLA reimbursement pathway of approximately $2,200 per test, the company possesses immediate commercialization pathways without the lengthy regulatory hurdles faced by early-stage diagnostics firms. The global cancer profiling market is estimated at $14 billion, with Ignite identifying $3 billion of serviceable opportunity among patients eligible for ADC and targeted therapies, representing a substantial addressable market that remains largely untapped due to limitations of current biomarker testing. Aditxt's social innovation platform model uniquely positions it to accelerate Ignite's growth by leveraging its ecosystem of research institutions and industry partners, as evidenced by ongoing collaborations with Dana-Farber, Vanderbilt, and Inova Health, which are generating real-world clinical validation data that could drive adoption beyond academic centers into community oncology practices. The appointment of Jeffrey M. Busch as Interim CEO of Aditxt, who brings proven public company leadership experience from building Global Medical REIT to over $1 billion in enterprise value while maintaining fiscal discipline, signals a strategic shift toward commercial execution and shareholder value creation, particularly as he previously achieved an 8.5% average annual dividend yield through disciplined capital stewardship in a regulated healthcare environment. This leadership transition, combined with Ignite's phased expansion plan targeting Molecular Tumor Boards and oncology practices where conventional biomarker guidance is limited, creates a clear pathway for revenue scaling as targeted therapies and ADCs continue to expand across tumor types, increasing demand for functional protein profiling tools that can determine true biological targets of therapy.

Aditxt's acquisition of Ignite Proteomics provides a significant strategic advantage in the precision oncology market, where Ignite's RPPA platform addresses a critical unmet need by measuring functional protein activity rather than just genomic expression, enabling more accurate therapy selection for targeted treatments like antibody drug conjugates. This technological differentiation is validated by peer-reviewed publication in npj Precision Oncology, demonstrating predictive value where conventional HER2 IHC failed, particularly in identifying TOPO1 expression in HER2-negative patients who may still benefit from T-DXd therapy. With Ignite already operating a CLIA-certified laboratory and having an established Medicare PLA reimbursement pathway of approximately $2,200 per test, the company possesses immediate commercialization pathways without the lengthy regulatory hurdles faced by early-stage diagnostics firms. The global cancer profiling market is estimated at $14 billion, with Ignite identifying $3 billion of serviceable opportunity among patients eligible for ADC and targeted therapies, representing a substantial addressable market that remains largely untapped due to limitations of current biomarker testing. Aditxt's social innovation platform model uniquely positions it to accelerate Ignite's growth by leveraging its ecosystem of research institutions and industry partners, as evidenced by ongoing collaborations with Dana-Farber, Vanderbilt, and Inova Health, which are generating real-world clinical validation data that could drive adoption beyond academic centers into community oncology practices. The appointment of Jeffrey M. Busch as Interim CEO of Aditxt, who brings proven public company leadership experience from building Global Medical REIT to over $1 billion in enterprise value while maintaining fiscal discipline, signals a strategic shift toward commercial execution and shareholder value creation, particularly as he previously achieved an 8.5% average annual dividend yield through disciplined capital stewardship in a regulated healthcare environment. This leadership transition, combined with Ignite's phased expansion plan targeting Molecular Tumor Boards and oncology practices where conventional biomarker guidance is limited, creates a clear pathway for revenue scaling as targeted therapies and ADCs continue to expand across tumor types, increasing demand for functional protein profiling tools that can determine true biological targets of therapy.

▼ Bear case

Aditxt faces substantial execution risks in commercializing Ignite Proteomics' platform despite its technological promise, as the company has a history of reverse stock splits—first a 1-for-8 split in March 2026 and now a 1-for-27 split effective May 2026—indicating persistent failure to maintain Nasdaq compliance due to chronically low stock price, which reflects underlying financial weakness and investor skepticism about near-term revenue generation. The recent acquisition of Ignite was structured through the issuance of 36,000 shares of Series A-2 Convertible Preferred Stock with an aggregate stated value of $36.0 million, representing significant dilution and potential overpayment for a subsidiary whose commercial traction remains unproven, especially given that Ignite's reimbursement pathway relies on a specific PLA code (0249U) that may face scrutiny or reimbursement pressure as utilization grows, potentially undermining the $2,200 per test economics. While Ignite claims a $3 billion serviceable opportunity in the ADC and targeted therapy market, this figure appears optimistic without clear disclosure of actual patient volumes, adoption rates, or sales pipeline, and the company's dependence on securing placements in Molecular Tumor Boards and oncology practices creates a lengthy sales cycle dependent on changing entrenched clinical workflows where genomic testing remains the standard of care. The leadership transition to Jeffrey M. Busch, while highlighting his public company experience, raises concerns as his background is primarily in healthcare REITs (Global Medical REIT/Chiron Real Estate), not diagnostics or biotech commercialization, and his prior success in generating dividend yields may not translate to a capital-intensive early-stage oncology diagnostics business requiring significant R&D and market education investments before profitability. Aditxt's own financial condition remains opaque due to the absence of recent earnings transcripts, but the repeated need for reverse stock splits suggests ongoing cash burn and inability to generate sufficient operating revenue, making the company dependent on dilutive financing or further asset sales to fund Ignite's expansion, which could erode shareholder value despite the promising science behind the RPPA platform.

Aditxt faces substantial execution risks in commercializing Ignite Proteomics' platform despite its technological promise, as the company has a history of reverse stock splits—first a 1-for-8 split in March 2026 and now a 1-for-27 split effective May 2026—indicating persistent failure to maintain Nasdaq compliance due to chronically low stock price, which reflects underlying financial weakness and investor skepticism about near-term revenue generation. The recent acquisition of Ignite was structured through the issuance of 36,000 shares of Series A-2 Convertible Preferred Stock with an aggregate stated value of $36.0 million, representing significant dilution and potential overpayment for a subsidiary whose commercial traction remains unproven, especially given that Ignite's reimbursement pathway relies on a specific PLA code (0249U) that may face scrutiny or reimbursement pressure as utilization grows, potentially undermining the $2,200 per test economics. While Ignite claims a $3 billion serviceable opportunity in the ADC and targeted therapy market, this figure appears optimistic without clear disclosure of actual patient volumes, adoption rates, or sales pipeline, and the company's dependence on securing placements in Molecular Tumor Boards and oncology practices creates a lengthy sales cycle dependent on changing entrenched clinical workflows where genomic testing remains the standard of care. The leadership transition to Jeffrey M. Busch, while highlighting his public company experience, raises concerns as his background is primarily in healthcare REITs (Global Medical REIT/Chiron Real Estate), not diagnostics or biotech commercialization, and his prior success in generating dividend yields may not translate to a capital-intensive early-stage oncology diagnostics business requiring significant R&D and market education investments before profitability. Aditxt's own financial condition remains opaque due to the absence of recent earnings transcripts, but the repeated need for reverse stock splits suggests ongoing cash burn and inability to generate sufficient operating revenue, making the company dependent on dilutive financing or further asset sales to fund Ignite's expansion, which could erode shareholder value despite the promising science behind the RPPA platform.

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	211.73 Bn	24.22	5.56	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	180.92 Bn	-62.49	5.94	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	132.16 Bn	30.00	10.50	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	82.89 Bn	19.15	5.34	1.99 Bn
5	ARGX	Argenx Se	primary	61.41 Bn	35.80	11.75	-
6	MRNA	Moderna, Inc.	primary	53.99 Bn	-17.13	24.23	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	34.48 Bn	44.51	7.18	-
8	BIIB	Biogen Inc.	primary	31.15 Bn	37.32	3.11	8.09 Bn

Aditxt ADTX

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password